Article

Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: A multistate study. Journal of Infectious Diseases., 205(1), 13-19

Oregon Public Health Division, Portland, OR 97212, USA.
The Journal of Infectious Diseases (Impact Factor: 5.78). 01/2012; 205(1):13-9. DOI: 10.1093/infdis/jir695
Source: PubMed

ABSTRACT Statins may have anti-inflammatory and immunomodulatory effects that could reduce the risk of mortality from influenza virus infections.
The Centers for Disease Control and Prevention's Emerging Infections Program conducts active surveillance for persons hospitalized with laboratory-confirmed influenza in 59 counties in 10 states. We analyzed data for hospitalized adults during the 2007-2008 influenza season to evaluate the association between receiving statins and influenza-related death.
We identified 3043 patients hospitalized with laboratory-confirmed influenza, of whom 1013 (33.3%) received statins and 151 (5.0%) died within 30 days of their influenza test. Patients who received statins were more likely to be older, male, and white; to suffer from cardiovascular, metabolic, renal, and chronic lung disease; and to have been vaccinated against influenza that season. In a multivariable logistic regression model, administration of statins prior to or during hospitalization was associated with a protective odds of death (adjusted odds ratio, 0.59 [95% confidence interval, .38-.92]) when adjusting for age; race; cardiovascular, lung, and renal disease; influenza vaccination; and antiviral administration.
Statin use may be associated with reduced mortality in patients hospitalized with influenza.

0 Followers
 · 
131 Views
  • Source
    • "As statins represent one of the most widely prescribed classes of drug in the world, identifying the capacity of statins to reduce influenza virus morbidity and mortality in the event of a pandemic or simply to extend the time between onset of illness and development of severe disease, thus allowing a greater window for the efficacy of existing antiviral treatments, is a matter of great public health importance. Despite conflicting reports, several retrospective observational studies have identified an association between statin use and reductions in influenza virus morbidity in humans; however, these studies are limited by the substantial variability in timing and duration of drug administration among participants, or the inclusion of pneumonia morbidity in the absence of laboratoryconfirmed influenza virus infection (Brett et al., 2011; Frost et al., 2007; Kwong et al., 2009; Mortensen et al., 2005; Vandermeer et al., 2012). Selected animal studies have further suggested a protective role for statins and other nonspecific antiinflammatory drug regimens against acute lung injury, but results have been mixed (Budd et al., 2007; Ferraro et al., 2011; Gower and Graham, 2001; Jacobson et al., 2005; Salomon et al., 2007; Walsh et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nonspecific anti-inflammatory drugs have been purported to reduce the burden of severe influenza disease. We demonstrate that, unlike oseltamivir administration, simvastatin administration did not reduce morbidity, mortality, or viral load of mice infected with H1N1 or H5N1 viruses. No added benefit to the efficacy of oseltamivir therapy was observed when mice were treated in combination with simvastatin. Modest reductions in lung cytokine production in H5N1 but not H1N1 virus-infected simvastatin-treated mice indicate a potential benefit for statin use in mitigating disease following severe virus infection.
    Virology 02/2013; 439(1). DOI:10.1016/j.virol.2013.01.017 · 3.28 Impact Factor
  • Source
    The Journal of Infectious Diseases 01/2012; 205(1):1-3. DOI:10.1093/infdis/jir693 · 5.78 Impact Factor
  • Source
    BMC Biology 01/2012; 10:6. DOI:10.1186/1741-7007-10-6 · 7.98 Impact Factor
Show more